The pull is a proposal DARPA did not fund. In 2018 EcoHealth Alliance, led by Peter Daszak, asked the Defense Advanced Research Projects Agency’s PREEMPT program for Project DEFUSE — “Defusing the Threat of Bat-borne Coronaviruses” — for $14,209,245. The document describes sampling SARS-related bat coronaviruses, reverse-engineering spike proteins, and inserting them into bat SARSr-CoV backbones to test whether they could cause SARS-like disease, plus cave work in Yunnan aimed at cutting viral shedding. Program manager James Gimlett’s source-selection summary marks the proposal selectable and does not recommend funding. He writes that the team aims to synthesize spike glycoproteins that may bind human cell receptors and insert them into SARSr-CoV backbones, that this approach does potentially involve gain-of-function or dual-use research of concern, and that the proposal does not mention or assess those risks. Adherent readers treat that paragraph as a blueprint for SARS-CoV-2. DARPA’s page is a rejection, not a work order. This page refuses both baptisms: “they built COVID,” and the sneer that noticing DEFUSE is irrational.
The Program They Applied To
PREEMPT — PREventing EMerging Pathogenic Threats — was a Biological Technologies Office program aimed at viral pathogens in animal reservoirs and insect vectors, before spillover, using biosurveillance, modeling, and interventions at the source. DARPA’s program page says the research was performed in controlled laboratory facilities, and that any later field trials would belong to other government stakeholders under ordinary biosafety rules. The program is now closed and kept online for reference. The 2018 DARPA note describes that approach. It is not a DEFUSE award.
DARPA — PREEMPT program page: https://www.darpa.mil/research/programs/preventing-emerging-pathogenic-threats
DARPA — “Going to the Source to Prevent Viral Disease Outbreaks” (2018): https://www.darpa.mil/news/2018/prevent-viral-disease-outbreak
What the Proposal and the PM Sheet Say
The EcoHealth proposal PDF, a redacted circulation copy, is the applicants’ document: a 2018 letter from Daszak, president of EcoHealth Alliance, under solicitation HR001118S0017. Technical passages discuss potential furin cleavage sites and, where mismatches occur, introducing human-specific cleavage changes to evaluate growth. A House Select Subcommittee report quotes Technical Area 1 in cleaner type: sequence spike proteins from bats at high-spillover sites, reverse-engineer them, insert them into WIV1 and SHC014 backbones — “bat-SARSr-CoV backbones, not SARS-CoV,” the proposal’s parenthetical — infect humanized mice, and assess capacity to cause SARS-like disease. Technical Area 2, as that report quotes it, evaluates immune boosting in bats and trials the most effective biologicals in cave sites in Yunnan, with reduced shedding as the proof of concept. The subcommittee records that Daszak raised Wuhan Institute of Virology collaborators with DARPA.
Gimlett’s PM summary sheet (solicitation HR001118S0017, proposal HR001118S0017-PREEMPT-FP-019) is DARPA’s form, not a blog recap. Two of three reviewers marked it selectable. Strengths listed include hotspot caves, prior surveillance, and experimental logic. The sheet then declines to recommend funding: regulatory and ethical, legal, and social issues are not discussed; vaccine-dose variability is not discussed; epitope coverage against diverse cave coronaviruses is a concern; data, statistics, and model development lack detail; decision points for trying preemption methods in the wild are unclear. It adds that the proposal discusses risk mitigation for public health and animal safety but does not mention or assess gain-of-function or DURC, and that if any component were later funded, a DURC mitigation plan including a responsible communications plan should be written into the contract. Some components, he writes, might be fundable if more money appeared. Neither line says the work was done.
EcoHealth — Project DEFUSE proposal PDF (redacted circulation copy): https://assets.ctfassets.net/syq3snmxclc9/4NFC6M83ewzKLf6DvAygb4/0cf477f75646e718afb332b7ac6c3cd1/defuse-proposal_watermark_Redacted.pdf
DARPA PM summary sheet — selectable, not recommended (Gimlett; image copy): https://drasticresearch.org/wp-content/uploads/2021/09/hr00118s017-preempt-fp-019-pm-summary-selectable-not-recommended.pdf
Two Accounts of Why It Failed
The House Select Subcommittee’s December 2024 after-action report quotes the proposal, records that DARPA marked DEFUSE “selectable, but not recommended,” and prints transcribed-interview answers. Gimlett identified a leaked letter as one he would have sent and said a lack of a gain-of-function or DURC plan did affect the decision to reject. Daszak testified that biosafety was not the reason given in a debrief, that the agency did not have the money, and that “too ambitious” was ordinary grant language. The report’s closing lines go further, writing that the work could have created a virus like COVID-19. That is the majority’s framing, not a sentence on Gimlett’s sheet. Daszak appears as the proposer and as a witness. Gimlett appears as the program manager who signed the sheet.
House Select Subcommittee — after-action report (4 December 2024), DEFUSE section: https://oversight.house.gov/wp-content/uploads/2024/12/12.04.2024-SSCP-FINAL-REPORT.pdf
On 1 May 2024 the subcommittee took public testimony from Daszak. He confirmed the DEFUSE submission. Asked about furin-cleavage experiments, he said the proposal was not funded and “the work was never done.” Members still read the furin-site design into the record. That denial is testimony, not a lab result. The hearing is not merged here into a lab-leak page.
GovInfo — Daszak hearing, Select Subcommittee (1 May 2024): https://www.govinfo.gov/content/pkg/CHRG-118hhrg55548/pdf/CHRG-118hhrg55548.pdf
Sibling Line
Lab-leak evidentiary pages, NIH grant files, and proximal-origin arguments are siblings. DEFUSE is the rejected DARPA proposal. Cross-reference. Do not merge them into one proof.
Refusal
Refuse “DEFUSE built COVID.” The agency’s own sheet does not recommend funding, and a proposal is not a virus. Refuse “only obsessives read a DARPA rejection that discusses furin sites and spike insertion.” The documents are public enough to quote. Contested clearance leaves both the blueprint reading and the coincidence reading on the table.
What the Paper Trail Settles
Documented: EcoHealth submitted DEFUSE to DARPA PREEMPT; the proposal text describes spike insertion into SARSr-CoV backbones and, in circulated pages, furin-cleavage edits; Gimlett’s summary calls it selectable, does not recommend funding, and flags unassessed GoF/DURC; Gimlett and Daszak later gave conflicting testimony on whether biosafety or money was the rejection’s point. Contested: whether the proposal is evidence that SARS-CoV-2 was built, and whether the subcommittee’s stronger causal sentences outrun the PM sheet. The Archive holds the documents at contested / L2.